Description of Tirzepatide
Tirzepatide is a dual receptor agonist targeting glucagon-like peptide-1 (GLP-1) receptor and insulinotropic polypeptide (GIP) receptor. Tirzepatide, developed by Lilly, is a chemically synthetic first-in-class peptide therapeutics for patients with type 2 diabetes, obesity, or overweight. It is licensed under the trade names Mounjaro and Zepbound.
Structural formula of tirzepatide
Yaohai Bio-Pharma offers tirzepatide as an active pharmaceutical ingredient (API)
| API, active substance | Application |
| Tirzepatide, GIP/GLP dual agonist | Tirzepatide API for injection formulation |
EN
